Picture loading failed.

Anti-CD38 therapeutic antibody (Pre-made Felzartamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38. ... The drug is currently in phase 3 of clinical trials for the treatment of multiple myeloma.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-208-1mg 1mg 3090
GMP-Bios-ab-208-10mg 10mg 21890
GMP-Bios-ab-208-100mg 100mg 148000
GMP-Bios-ab-208-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD38 therapeutic antibody (Pre-made Felzartamab biosimilar,Whole mAb)
INN Name Felzartamab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
Conditions Approvedna
Conditions ActiveMultiple myeloma;Membranous glomerulonephritis;Leukemia;Systemic lupus erythematosus
Conditions DiscontinuedNon-small cell lung cancer
Development Techna